<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31719007</article-id><article-id pub-id-type="pmc">6852443</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2019-0062</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Relationship Between Mitral Annular Calcification, Metabolic
Syndrome and Thromboembolic Risk</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6480-4935</contrib-id><name><surname>Aksoy</surname><given-names>Fatih</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Guler</surname><given-names>Serdar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Kahraman</surname><given-names>Fatih</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Kuyumcu</surname><given-names>Mevl&#x000fc;t Serdar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Bagc&#x00131;</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Bas</surname><given-names>Hasan Ayd&#x00131;n</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Uysal</surname><given-names>Din&#x000e7;er</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Varol</surname><given-names>Ercan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib></contrib-group><aff id="aff1">
<label>1</label>Department of Cardiology, Suleyman Demirel University, Medical
School, Isparta, Turkey.</aff><aff id="aff2">
<label>2</label>Department of Cardiovascular Surgery, Suleyman Demirel University,
Medical School, Isparta, Turkey.</aff><author-notes><corresp id="c1">Correspondence Address: <bold>Fatih Aksoy</bold>, <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-6480-4935">https://orcid.org/0000-0002-6480-4935</ext-link>, Department of Cardiology,
Suleyman Demirel University, Medical School, &#x000c7;&#x000fc;n&#x000fc;r
Mahallesi, S&#x000fc;leyman Demirel Cd., Isparta, Turkey, Zip code: 32260.
E-mail: <email>dr.aksoy@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2019</year></pub-date><volume>34</volume><issue>5</issue><fpage>535</fpage><lpage>541</lpage><history><date date-type="received"><day>13</day><month>2</month><year>2019</year></date><date date-type="accepted"><day>01</day><month>3</month><year>2019</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Metabolic syndrome (MetS) is defined as an association between diabetes,
hypertension, obesity and dyslipidemia and an increased risk of
cardiovascular disease. Mitral annular calcification (MAC) is associated
with several cardiovascular disorders, including coronary artery disease,
atrial fibrillation (AF), heart failure, ischemic stroke and increased
mortality. The CHA<sub>2</sub>DS<sub>2</sub>-VASc score is used to estimate
thromboembolic risk in AF. However, the association among MAC, MetS and
thromboembolic risk is unknown and was evaluated in the current study.</p></sec><sec><title>Methods</title><p>The study group consisted of 94 patients with MAC and 86 patients with MetS.
Patients were divided into two groups: those with and those without MAC.</p></sec><sec><title>Results</title><p>Patients with MAC had a higher MetS rate (<italic>P</italic>&#x0003c;0.001). In
patients with MAC, the CHA<sub>2</sub>DS<sub>2</sub>-VASc scores and the
rate of cerebrovascular accident and AF were significantly higher compared
to those without MAC (<italic>P</italic>&#x0003c;0.001, for both parameters). The
results of the multivariate regression analysis showed that history of
smoking, presence of MetS and high CHA<sub>2</sub>DS<sub>2</sub>-VASc scores
were associated with the development of MAC. ROC curve analyses showed that
CHA<sub>2</sub>DS<sub>2</sub>-VASc scores were signi&#x0fb01;cant predictors for
MAC (C-statistic: 0.78; 95% CI: 0.706-0.855, <italic>P</italic>&#x0003c;0.001).
Correlation analysis indicated that MAC was positively correlated with the
presence of MetS and CHA<sub>2</sub>DS<sub>2</sub>-VASc score
(<italic>P</italic>=0.001, r=0.264; <italic>P</italic>&#x0003c;0.001,
r=0.490).</p></sec><sec><title>Conclusion</title><p>We have shown that CHA<sub>2</sub>DS<sub>2</sub>-VASc score and presence of
MetS rates were significantly higher in patients with MAC compared without
MAC. Presence of MAC was correlated with CHA<sub>2</sub>DS<sub>2</sub>-VASc
score, presence of MetS, AF and left atrial diameter and negatively
correlated with left ventricular ejection fraction.</p></sec></abstract><kwd-group><kwd>Atrial Fibrilation</kwd><kwd>Stroke</kwd><kwd>Metabolic Syndrome</kwd><kwd>Coronary Artery Disease</kwd><kwd>Brain Ischemia</kwd><kwd>Thromboembolism</kwd><kwd>Hypertension</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="4%" span="1"/><col width="44%" span="1"/><col width="4%" span="1"/><col width="4%" span="1"/><col width="44%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVESD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
end-systolic diameter</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BMP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Bone morphogenic
protein</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVPW</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
posterior wall</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MAC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Mitral annular
calcification</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CVA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cerebrovascular
accident</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MetS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Metabolic syndrome</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HDL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= High-density
lipoprotein</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MESA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Multi-Ethnic Study of
Atherosclerosis</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IQR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Interquartile range</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Odds ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IVS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Interventricular
septum</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Oxidative stress</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left atrial</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ROC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Receiver operating
characteristics</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TIA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transient ischemic
attack</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEDD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
end-diastolic diameter</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Mitral annular calcification (MAC) is a chronic, age-related, non-inflammatory
degenerative process affecting the fibrous annulus of the mitral valve<sup>[<xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Recent studies demonstrated the strong association between the
coexistence of MAC and cardiovascular risk factors<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. In
addition, studies have shown a relationship between MAC and carotid and peripheral
artery disease<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>. MAC is accompanied by mitral valve disease and
arrhythmias, including atrial fibrillation (AF) and conduction system disease and
influenced the outcome of cardiac surgery<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Although it is
most commonly asymptomatic and an incidental finding, its clinical relevance comes
from the association of MAC with an increased rate of mortality and cardiovascular
disease<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. Additionally, a
strong correlation was shown between MAC and risk of stroke<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Coexistence of MAC and stroke can
be explained by cardiovascular risk factors, mitral valve disease and arrhythmias,
including AF.</p><p>Metabolic syndrome (MetS) is a cluster of conditions including metabolic
abnormalities, abdominal obesity, high blood pressure, hyperglycemia, low
high-density lipoprotein (HDL) cholesterol levels, and high triglyceride levels.
Additionally, patients with MetS have higher risk for heart disease, stroke and
diabetes<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>The CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score is an inexpensive and easy scoring
system that is calculated by assigning a score of 1 point for each of the following
conditions: congestive heart failure (ejection fraction &#x0003c;40%), hypertension, age
between 65 and 74 years, diabetes mellitus, vascular disease (myocardial infarction
or peripheral arterial disease) and female gender; a score of 2 points for the
following conditions: history of stroke or transient ischemic attack (TIA) and age
&#x0003e;75 years. The CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score is used to predict
the risk of thromboembolism in patients with non-valvular AF<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>In this study, we aimed to investigate the relationship between MAC, MetS and
thromboembolic risk.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study Population</title><p>The 164 consecutive patients (78 females, 86 males, mean age 70.6&#x000b1;6.3
years) admitted to Suleyman Demirel University Hospital, Department of
Cardiology outpatient clinic, and referred to our echocardiography laboratory
due to suspicion of heart disease between June 2015 and May 2016 were enrolled
in this prospective study. All patients underwent medical history, physical
examination, anthropometric measurements, electrocardiogram, and
echocardiographic evaluation. The study was approved by the institutional ethics
committee and all patients gave their informed consent. Exclusion criteria were
pericardial effusion, poor echocardiographic window, and history of chronic
renal and liver disease, moderate to severe mitral and aortic regurgitation,
moderate to severe mitral and aortic stenosis, malignancy, systemic or pulmonary
embolism, chronic hematological diseases, acute or chronic inflammatory disease,
autoimmune disease, hyperparathyroidism, hypercalcemia, hyperphosphatemia and
presence of prosthetic valve. Patients were divided into two groups, according
to the presence of MAC in echocardiographic evaluation.</p></sec><sec><title>Echocardiography</title><p>The M-mode, 2D and Doppler echocardiographic examinations were obtained by GE
VingMed System FiVe (Norway) to assess left atrial (LA) diameter,
interventricular septum (IVS) thickness, left ventricular posterior wall (LVPW)
thickness, left ventricular-end diastolic diameter (LVEDD), left ventricular
end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF) and
MAC. Left atrial and ventricular dimensions and LVEF were measured by M-mode
echocardiography in the parasternal long axis view using the American
Echocardiography Society M-mode technique<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. MAC was defined as an intense
echocardiographic-producing structure with highly reflective characteristics
that was located at the junction of the atrioventricular groove and the
posterior or anterior mitral leaflet on the parasternal long-axis, apical
4-chamber or 2-chamber, or parasternal short-axis view<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. The presence of mitral and
aortic insufficiency was evaluated by Doppler color flow mapping.</p></sec><sec><title>Metabolic Syndrome</title><p>At inclusion, MetS was defined according to the National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III) criteria as &#x02265;3 of the
following: (i) waist circumference &#x02265;88 cm in women and &#x02265;102 cm in
men; (ii) elevated plasma triglycerides (&#x02265;1.7 mmol/L), or treatment for
high triglycerides; (iii) low-plasma HDL-C (&#x0003c;1.3 mmol/L for women and
&#x0003c;1.04 mmol/L for men); (iv) high fasting plasma glucose (&#x02265;5.6 mmol/L),
or diabetes treatment; and (v) blood pressure &#x02265;130/80 mmHg, or treated
hypertension<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p></sec><sec><title>Statistical Analysis</title><p>SPSS version 16.0 software package was used for statistical analyses in this
study. Categorical variables were expressed as frequency (%) and compared with
the &#x003c7;2 test. Kolmogorov-Smirnov test was used to test the distribution of
numerical variables; those with normal distribution were expressed as mean
&#x000b1; standard deviation and were compared with Student&#x02019;s t-test. Data
without normal distribution were expressed as median [interquartile range (IQR)
of 25%-75% percentiles] and were compared with the Mann-Whitney U test. In all
statistical analyses, <italic>P</italic>-value &#x0003c;0.05 was considered
statistically significant. The correlations between
CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score, presence of MetS, presence of
MAC and other clinical, laboratory and echocardiographic parameters were
performed with Pearson or Spearman correlation analysis when appropriate.
Univariate analysis of binary logistic regression was carried out to identify
which factors were associated with the presence of MAC. After including each of
these potential confounding factors, backward conditional binary logistic
regression analysis was performed to estimate the odds ratio (OR) and 95%
confidence interval (95% CI) for presence of MAC. Receiver operating
characteristics (ROC) curve analysis was used to analyze the prognostic value of
CHA<sub>2</sub>DS<sub>2</sub>-VASc score for presence of MAC. C-Statistic
(area under the curve) was presented as a unified estimate of sensitivity and
specificity.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 164 patients (mean age: 70.6 &#x000b1; 6.3 years; range 52-85 years) were
included in this study. In the echocardiographic evaluation, MAC was diagnosed in 94
patients. Demographic, clinical, laboratory and echocardiographic characteristics of
the patients with and without MAC are listed in <xref rid="t1" ref-type="table">Table 1</xref>. Patients with MAC were generally older, more diabetic and more
hypertensive when compared to patients without MAC (<italic>P</italic>&#x0003c;0.001,
<italic>P</italic>&#x0003c;0.001 and <italic>P</italic>=0.001, respectively).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic, clinical, laboratory and echocardiographic characteristics of
the patients with and without MAC.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">MAC (-) (n=70)</th><th align="center" rowspan="1" colspan="1">MAC (+) (n=94)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="center" rowspan="1" colspan="1">68.4&#x000b1;4.5</td><td align="center" rowspan="1" colspan="1">72.2&#x000b1;7.0</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Female gender, n (%)</td><td align="center" rowspan="1" colspan="1">30 (42)</td><td align="center" rowspan="1" colspan="1">45 (51)</td><td align="center" rowspan="1" colspan="1">0.189</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, n (%)</td><td align="center" rowspan="1" colspan="1">29 (41)</td><td align="center" rowspan="1" colspan="1">66 (70)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="center" rowspan="1" colspan="1">17 (24)</td><td align="center" rowspan="1" colspan="1">47 (50)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipidemia, n (%)</td><td align="center" rowspan="1" colspan="1">33 (47)</td><td align="center" rowspan="1" colspan="1">45 (47)</td><td align="center" rowspan="1" colspan="1">0.526</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking, n (%)</td><td align="center" rowspan="1" colspan="1">19 (27)</td><td align="center" rowspan="1" colspan="1">42 (44)</td><td align="center" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" rowspan="1" colspan="1">CAD, n (%)</td><td align="center" rowspan="1" colspan="1">8 (11)</td><td align="center" rowspan="1" colspan="1">23 (24.5)</td><td align="center" rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" rowspan="1" colspan="1">CVA/TIA, n (%)</td><td align="center" rowspan="1" colspan="1">1 (1.4)</td><td align="center" rowspan="1" colspan="1">12 (12.8)</td><td align="center" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">29.0&#x000b1;5.1</td><td align="center" rowspan="1" colspan="1">30.9&#x000b1;7.2</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="center" rowspan="1" colspan="1">97.4&#x000b1;12.4</td><td align="center" rowspan="1" colspan="1">101.0&#x000b1;11.0</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">118.0&#x000b1;17</td><td align="center" rowspan="1" colspan="1">121.0&#x000b1;17</td><td align="center" rowspan="1" colspan="1">0.182</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">75.0&#x000b1;8.1</td><td align="center" rowspan="1" colspan="1">77.0&#x000b1;10.3</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (beat/min)</td><td align="center" rowspan="1" colspan="1">70.1&#x000b1;12.4</td><td align="center" rowspan="1" colspan="1">71.7&#x000b1; 13.6</td><td align="center" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin, n (%)</td><td align="center" rowspan="1" colspan="1">16 (22)</td><td align="center" rowspan="1" colspan="1">25 (26)</td><td align="center" rowspan="1" colspan="1">0.359</td></tr><tr><td align="left" rowspan="1" colspan="1">ACEi, n (%)</td><td align="center" rowspan="1" colspan="1">13 (18)</td><td align="center" rowspan="1" colspan="1">25 (26)</td><td align="center" rowspan="1" colspan="1">0.154</td></tr><tr><td align="left" rowspan="1" colspan="1">ARB, n (%)</td><td align="center" rowspan="1" colspan="1">14 (20)</td><td align="center" rowspan="1" colspan="1">24 (25)</td><td align="center" rowspan="1" colspan="1">0.261</td></tr><tr><td align="left" rowspan="1" colspan="1">OAD, n (%)</td><td align="center" rowspan="1" colspan="1">7 (10)</td><td align="center" rowspan="1" colspan="1">32 (34)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin, n (%)</td><td align="center" rowspan="1" colspan="1">4 (5.7)</td><td align="center" rowspan="1" colspan="1">11 (11.7)</td><td align="center" rowspan="1" colspan="1">0.149</td></tr><tr><td align="left" rowspan="1" colspan="1">MetS, n (%)</td><td align="center" rowspan="1" colspan="1">26 (37)</td><td align="center" rowspan="1" colspan="1">60 (63)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td><td align="center" rowspan="1" colspan="1">2.1&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">3.5&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">High risk group for CHA<sub>2</sub>DS<sub>2</sub>-VASc
score</td><td align="center" rowspan="1" colspan="1">42 (60)</td><td align="center" rowspan="1" colspan="1">86 (91)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet count (&#x000d7; 10<sup>3</sup>/&#x000b5;L)</td><td align="center" rowspan="1" colspan="1">248&#x000b1;81</td><td align="center" rowspan="1" colspan="1">242&#x000b1;61</td><td align="center" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">White blood cell count (&#x000d7;
10<sup>3</sup>/&#x000b5;L)</td><td align="center" rowspan="1" colspan="1">8.032&#x000b1;2.137</td><td align="center" rowspan="1" colspan="1">7.775&#x000b1;2.618</td><td align="center" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol, mg/dL</td><td align="center" rowspan="1" colspan="1">47.1&#x000b1;15.9</td><td align="center" rowspan="1" colspan="1">47.1&#x000b1;11.9</td><td align="center" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol, mg/dL</td><td align="center" rowspan="1" colspan="1">108.4&#x000b1;38.8</td><td align="center" rowspan="1" colspan="1">113.6&#x000b1;38.3</td><td align="center" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides, mg/dL</td><td align="center" rowspan="1" colspan="1">154.1&#x000b1;119.22</td><td align="center" rowspan="1" colspan="1">147.9&#x000b1;75.3</td><td align="center" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose, mg/dL</td><td align="center" rowspan="1" colspan="1">122.6&#x000b1;58.6</td><td align="center" rowspan="1" colspan="1">123.9&#x000b1;57.6</td><td align="center" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine, mg/dL)</td><td align="center" rowspan="1" colspan="1">0.9 &#x000b1;0.1</td><td align="center" rowspan="1" colspan="1">0.9 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol, mg/dL</td><td align="center" rowspan="1" colspan="1">184.7&#x000b1;57.5</td><td align="center" rowspan="1" colspan="1">190&#x000b1;47.4</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF, %</td><td align="center" rowspan="1" colspan="1">60 &#x000b1;2.2</td><td align="center" rowspan="1" colspan="1">58.7&#x000b1;4.1</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Aorta (mm)</td><td align="center" rowspan="1" colspan="1">24.9 &#x000b1;2.3</td><td align="center" rowspan="1" colspan="1">25.9&#x000b1;2.3</td><td align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">LA (mm)</td><td align="center" rowspan="1" colspan="1">34.7&#x000b1;4.8</td><td align="center" rowspan="1" colspan="1">37.4&#x000b1;4.3</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">IVS (mm)</td><td align="center" rowspan="1" colspan="1">10.5&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">11.2&#x000b1;1.4</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LVPW (mm)</td><td align="center" rowspan="1" colspan="1">9.6&#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">10&#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">LVESD (mm)</td><td align="center" rowspan="1" colspan="1">27&#x000b1;2.3</td><td align="center" rowspan="1" colspan="1">28&#x000b1;3.3</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEDD (mm)</td><td align="center" rowspan="1" colspan="1">44.6&#x000b1;2.5</td><td align="center" rowspan="1" colspan="1">46.2&#x000b1;3.2</td><td align="center" rowspan="1" colspan="1">0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor
blocker; BMI=body mass index; CAD=coronary artery disease; DBP=diastolic
blood pressure; HDL=High density lipoprotein; IVS=interventricular
septum; LA=left atrium; LDL=low density lipoprotein; LVEDD=left
ventricular end diastolic diameter; LVEF=left ventricular ejection
fraction; LVESD=left ventricular end systolic diameter; LVPW=left
ventricular posterior wall; MAC=mitral annular calcification;
MetS=metabolic syndrome; OAD=oral antidiabetics; SBP=systolic blood
pressure; TIA=transient ischemic attack</p></fn></table-wrap-foot></table-wrap><p>Smoking, coronary artery disease (CAD) and stroke/TIA rates were higher in patients
with MAC than patients without MAC (<italic>P</italic>=0.016,
<italic>P</italic>=0.026 and <italic>P</italic>=0.006, respectively). Hyperlipidemia
and gender were similar between patients with and without MAC (for both parameters,
<italic>P</italic>&#x0003e;0.05). MetS rates were higher in patients with MAC
(<italic>P</italic>=0.001). Patients with MAC had higher
CHA<sub>2</sub>DS<sub>2</sub>-VASc scores than patients without MAC
(<italic>P</italic>&#x0003c;0.001). When, according to
CHA<sub>2</sub>DS<sub>2</sub>-VASc score, patients were divided into two groups,
with 0 and 1 scores considered as low risk, and &#x02265;2 scores considered as high
risk, patients with MAC had a higher rate of high risk category than patients
without MAC (<italic>P</italic>&#x0003c;0.001). There was no statistically significant
difference between two groups for cholesterol and glucose levels (for both
parameters, <italic>P</italic>&#x0003e;0.05). LA diameter was significantly higher in
patients with MAC than without MAC (37.4&#x000b1;4.3 <italic>vs</italic>.
34.7&#x000b1;4.8 mm, respectively; <italic>P</italic>&#x0003c;0.001). IVS thickness was
significantly higher in patients with MAC than without MAC (11.2&#x000b1;1.4
<italic>vs</italic>. 10.5&#x000b1;1.3 mm, respectively;
<italic>P</italic>=0.001). LVEDD was significantly higher in patients with MAC than
without MAC (46.2&#x000b1;3.2 <italic>vs</italic>. 44.6&#x000b1;2 mm, respectively;
<italic>P</italic>=0.001). LVESD was significantly higher in patients with MAC
than without MAC (28&#x000b1;3.3 <italic>vs</italic>. 27&#x000b1;2.3 mm, respectively;
<italic>P</italic>&#x0003c;0.001).</p><sec><title>Binary Logistic Regression for MAC</title><p>Correlation analysis indicated that MAC was positively correlated with
CHA<sub>2</sub>DS<sub>2</sub>-VASc score (<italic>P</italic>&#x0003c;0.001,
r=0.49), AF (<italic>P</italic>=0.008, r=0.208), LA diameter
(<italic>P</italic>=0.001, r=0.267), age (<italic>P</italic>&#x0003c;0.001, r=0.347),
history of hypertension (<italic>P</italic>&#x0003c;0.001, r=0.288), history of
diabetes mellitus (<italic>P</italic>=0.001, r=0.261), presence of MetS
(<italic>P</italic>=0.001, r=0.264), history of smoking
(<italic>P</italic>=0.021, r=0.179), history of cerebrovascular
accident/transient ischemic attack (CVA/TIA) (<italic>P</italic>=0.008,
r=0.208), presence of AF (<italic>P</italic>=0.008, r=0.208), and negatively
correlated with LVEF (<italic>P</italic>=0.021, r= -0.18) (<xref rid="t2" ref-type="table">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Correlation of mitral annular calcification with variables.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score</th><th align="center" rowspan="1" colspan="1">Age</th><th align="center" rowspan="1" colspan="1">Hypertension</th><th align="center" rowspan="1" colspan="1">Diabetes mellitus</th><th align="center" rowspan="1" colspan="1">LA <break/>diameter</th><th align="center" rowspan="1" colspan="1">LVEF</th><th align="center" rowspan="1" colspan="1">MetS</th><th align="center" rowspan="1" colspan="1">Smoking</th><th align="center" rowspan="1" colspan="1">CVA/TIA</th><th align="center" rowspan="1" colspan="1">AF</th></tr></thead><tbody><tr><td rowspan="2" align="left" valign="top" colspan="1">MAC</td><td align="center" rowspan="1" colspan="1">r</td><td align="center" rowspan="1" colspan="1">0.490</td><td align="center" rowspan="1" colspan="1">0.347</td><td align="center" rowspan="1" colspan="1">0.288</td><td align="center" rowspan="1" colspan="1">0.261</td><td align="center" rowspan="1" colspan="1">0.267</td><td align="center" rowspan="1" colspan="1">-0.180</td><td align="center" rowspan="1" colspan="1">0.264</td><td align="center" rowspan="1" colspan="1">0.179</td><td align="center" rowspan="1" colspan="1">0.208</td><td align="center" rowspan="1" colspan="1">0.208</td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic></td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">0.021</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">0.021</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1">0.008</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>AF=atrial fibrillation; CVA=cerebrovascular accident; LA=left atrium;
LVEF=left ventricular ejection fraction; TIA=transient ischemic
attack</p></fn></table-wrap-foot></table-wrap><p>Univariate analysis showed that high CHA<sub>2</sub>DS<sub>2</sub>-VASc score and
group, presence of MetS, advanced age, history of hypertension, history of
diabetes mellitus and history of smoking were significantly associated with a
higher risk of MAC (<xref rid="t3" ref-type="table">Table 3</xref>). A
multivariate binary logistic regression analysis was carried out including all
the characteristics associated with MAC in the univariate analysis. This
analysis showed that high risk according to the
CHA<sub>2</sub>DS<sub>2</sub>-VASc score (OR: 5.0; 95% CI: 2.0-12.5,
<italic>P</italic>&#x0003c;0.001), presence of MetS (OR: 1.002; 95% CI:
1.00-1.003, <italic>P</italic>=0.014) and history of smoking (OR: 2.09; 95% CI:
1.00-4.35, <italic>P</italic>=0.049) remained as independent factors for MAC.
ROC curve analysis showed that CHA<sub>2</sub>DS<sub>2</sub>-VASc score
(C-statistic: 0.78; 95% CI: 0.706-0.855, <italic>P</italic>&#x0003c;0.001) were
significant predictors of MAC (<xref ref-type="fig" rid="f1">Figure 1</xref>).
We calculated that a cut-off point of 2.5 for CHA<sub>2</sub>DS<sub>2</sub>-VASc
scores could estimate the presence of MAC with a sensitivity of 81% and 70%.
When univariate analysis was carried out for CVA/TIA, presence of MAC increased
10-fold the CVA/TIA risk (OR: 10, 09; 95% CI: 1.28-79.62,
<italic>P</italic>=0.028).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Predictors of mitral annular calcification in univariate and multivariate
logistic regression analysis.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="28%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Unadjusted OR</th><th align="center" rowspan="1" colspan="1">CI 95%</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="center" rowspan="1" colspan="1">Adjusted OR</th><th align="center" rowspan="1" colspan="1">CI 95%</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="center" rowspan="1" colspan="1">1.106</td><td align="center" rowspan="1" colspan="1">1.04-1.16</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">3.33</td><td align="center" rowspan="1" colspan="1">1.74-6.37</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">3.11</td><td align="center" rowspan="1" colspan="1">1.58-6.15</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">History of smoking</td><td align="center" rowspan="1" colspan="1">2.16</td><td align="center" rowspan="1" colspan="1">1.11-4.21</td><td align="center" rowspan="1" colspan="1">0.023</td><td align="center" rowspan="1" colspan="1">2.09</td><td align="center" rowspan="1" colspan="1">1.00-4.35</td><td align="center" rowspan="1" colspan="1">0.049</td></tr><tr><td align="left" rowspan="1" colspan="1">MetS</td><td align="center" rowspan="1" colspan="1">2.98</td><td align="center" rowspan="1" colspan="1">1.57-5.6</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">2.44</td><td align="center" rowspan="1" colspan="1">1.20-4.96</td><td align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc group (high
risk)</td><td align="center" rowspan="1" colspan="1">7.1</td><td align="center" rowspan="1" colspan="1">3.0-17.0</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">5.0</td><td align="center" rowspan="1" colspan="1">2.0-12.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td><td align="center" rowspan="1" colspan="1">2.26</td><td align="center" rowspan="1" colspan="1">1.68-3.0</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>ROC curve with calculated area under the curve and optimal cut-off
point for CHA2DS2-VASc score to identify the presence of MAC.
C-statistic (area under the curve) &#x02014; 95% con&#x0fb01;dence interval (95%
CI): CHA2DS2-VASc: (C-statistic: 0.78; 95% CI: 0.706-0.855,
P&#x0003c;0.001). We calculated the cut-off point of 2.5 for CHA2DS2-VASc
score to estimate the presence of MAC with a sensitivity of 81% and
70%.</p></caption><graphic xlink:href="rbccv-34-05-0535-g01"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The current study showed that higher CHA<sub>2</sub>DS<sub>2</sub>-VASc scores and
presence of MetS were independently associated with the development of MAC;
consequently, individuals at high risk according to
CHA<sub>2</sub>DS<sub>2</sub>-VASc scores and presence of MetS should receive more
attention to reduce unfavorable cardiovascular risk factors and the development of
future cardiovascular events. The other finding of the study determined that the
presence of MAC increased the risk of CVA/TIA and AF.</p><p>CHA<sub>2</sub>DS<sub>2</sub>-VASc score was associated with in-hospital and
long-term adverse clinical outcomes, including mortality, in patients with stable
CAD and acute coronary syndrome <sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>]</sup>. To the best of
our knowledge, there is no study investigating the relationship between
CHA<sub>2</sub>DS<sub>2</sub>-VASc score, MetS and MAC, which has similar risk
factors for atherosclerotic heart disease.</p><p>Since MAC is often associate with coronary risk factors, such as hypertension,
diabetes and obesity<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>, it is
possible that convergence of multiple risk factors could potentiate cardiovascular
risk. This is exemplified by MetS. MAC is largely thought to be a manifestation of
atherosclerotic coronary heart disease. This is mainly because the risk factors for
MAC have been found to be similar to that of coronary artery disease, sharing a
common pathogenesis for atherosclerosis.</p><p>MAC is associated with several cardiovascular disorders, including CAD, carotid and
aortic atherosclerosis, heart failure, and stroke<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Previous studies have determined
that age, hypertension, diabetes mellitus, and obesity, which are risk factors for
atherosclerotic heart disease, are also risk factors for MAC<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>. In our study, we have found higher rates of diabetes mellitus
and hypertension, which are a component of MetS and
CHA<sub>2</sub>DS<sub>2</sub>-VASc score, in patients with MAC than in controls, and
our results are consistent with previous studies of this aspect<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>. Bone morphogenic protein (BMP) 2, which is the key of
osteogenic regulatory factor, is upregulated by hyperglycemia in vitro<sup>[<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r18" ref-type="bibr">18</xref>]</sup>. BMP2 showed to play a role in vascular
calcification<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> and has
been detected in areas of valvular calcification<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. Another theory that explained increased calcium
in mitral annulus is the pro-oxidative status in diabetes mellitus. Oxidative stress
(OS) is caused by increased production of reactive oxygen species. Increased
oxidative products lead to cell death or to acceleration in ageing and age-related
disease<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Besides, OS
not only plays a role in the pathogenesis of MAC and may explain increased mortality
and morbidity in patients with MAC. OS is also known to regulate different stages of
thrombotic processes, including platelet activation. OS may trigger platelet
hyperactivity, reducing nitric oxide bioavailability<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>. Additionally, OS have a role in the metabolic
syndrome process<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. Thus,
increasing OS may play a role in increased mortality and morbidity in patients with
MAC.</p><p>Studies have demonstrated that MetS was associated with increased rates of aortic
stenosis progression and bioprosthetic valve deterioration<sup>[<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>. In Multi-Ethnic Study of Atherosclerosis (MESA) cohort,
Katz et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>showed that MetS
was associated with new and older aortic valve. In our study, we demonstrated that
patients with MetS had higher MAC rates than patients without MetS. In the
MESA<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>, investigators
examined the association between MAC and AF in a racially and ethnically diverse
population. They found that MAC was associated with an increased risk of AF (HR=1.9,
95% CI=1.5, 2.5). Hypertension and diabetes mellitus were more seen in patients with
MAC than without MAC. Additionally, patients with MAC had left ventricular
hypertrophy and left atrial enlargement more explicit than patients without MAC.
Similarly, in the present study, we found that hypertension and diabetes mellitus
were more observed in patients with MAC than without MAC. In addition, we have also
found higher left atrial diameter, lower ejection fraction and higher incidence of
left ventricular hypertrophy in patients with MAC than in controls. These findings
may explain the association of MAC with adverse cardiovascular events, including
stroke and increased mortality. Our other finding that AF and CVA/TIA were more seen
in patients with MAC than without MAC, was consistent with left atrial dilatation
and left ventricular hypertrophy. Our results are consistent with previous studies
also in this respect<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>The global prevalence of MetS has increased due to the increased rates of obesity and
sedentary lifestyle and has been associated with a higher risk of major adverse
cardiac events in the general population<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. Individuals with MetS should receive more attention to
reduce unfavorable cardiovascular risk factors and the development of future
cardiovascular events. Additionally, lifestyle changes and cardiovascular risk
modification may reduce cardiac structural changes, such as left atrial dilatation,
left ventricular hypertrophy and MAC formation.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In conclusion, we showed that CHA<sub>2</sub>DS<sub>2</sub>-VASc score and presence
of MetS rates were significantly higher in patients with MAC compared with controls.
MAC was correlated with CHA<sub>2</sub>DS<sub>2</sub>-VASc score, presence of MetS,
AF and left atrial diameter and negatively correlated with LVEF. The
CHA<sub>2</sub>DS<sub>2</sub>-VASc score and presence of MetS were independently
associated with presence of MAC. Presence of MetS and high
CHA<sub>2</sub>DS<sub>2</sub>-VASc scores may indicate that patients with MAC
have a higher risk of systemic thromboembolism.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">FA</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SG</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FK</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MSK</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AB</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HAB</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DU</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EV</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important&#x000a0; intellectual content; final approval of
the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Suleyman Demirel University Education and Research
Hospital, Isparta, Turkey.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>Y</given-names></name><name><surname>Fink</surname><given-names>N</given-names></name><name><surname>Spector</surname><given-names>D</given-names></name><name><surname>Wiser</surname><given-names>I</given-names></name><name><surname>Sagie</surname><given-names>A</given-names></name></person-group><article-title>Mitral annulus calcification-a window to diffuse atherosclerosis
of the vascular system</article-title><source>Atherosclerosis</source><year>2001</year><volume>155</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/s0021-9150(00)00737-1</pub-id><pub-id pub-id-type="pmid">11223420</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanjanauthai</surname><given-names>S</given-names></name><name><surname>Nasir</surname><given-names>K</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>Rivera</surname><given-names>JJ</given-names></name><name><surname>Takasu</surname><given-names>J</given-names></name><name><surname>Blumenthal</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Relationships of mitral annular calcification to cardiovascular
risk factors: the multi-ethnic study of atherosclerosis
(MESA)</article-title><source>Atherosclerosis</source><year>2010</year><volume>213</volume><issue>2</issue><fpage>558</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2010.08.072</pub-id><pub-id pub-id-type="pmid">20926076</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariyarajah</surname><given-names>V</given-names></name><name><surname>Apiyasawat</surname><given-names>S</given-names></name><name><surname>Barac</surname><given-names>I</given-names></name><name><surname>Spodick</surname><given-names>DH</given-names></name></person-group><article-title>Is the presence of mitral annular calcification associated with
poor left atrial function?</article-title><source>Echocardiography</source><year>2009</year><volume>26</volume><issue>8</issue><fpage>877</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8175.2009.00900.x</pub-id><pub-id pub-id-type="pmid">19486115</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barasch</surname><given-names>E</given-names></name><name><surname>Gottdiener</surname><given-names>JS</given-names></name><name><surname>Larsen</surname><given-names>EKM</given-names></name><name><surname>Chaves</surname><given-names>PH</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><name><surname>Manolio</surname><given-names>TA</given-names></name></person-group><article-title>Clinical significance of calcification of the fibrous skeleton of
the heart and aortosclerosis in community dwelling elderly. The
cardiovascular health study (CHS)</article-title><source>Am Heart J</source><year>2006</year><volume>151</volume><issue>1</issue><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2005.03.052</pub-id><pub-id pub-id-type="pmid">16368289</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neal</surname><given-names>WT</given-names></name><name><surname>Efird</surname><given-names>JT</given-names></name><name><surname>Nazarian</surname><given-names>S</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Heckbert</surname><given-names>SR</given-names></name><name><surname>Soliman</surname><given-names>EZ</given-names></name></person-group><article-title>Mitral annular calcification and incident atrial fibrillation in
the multi-ethnic study of atherosclerosis</article-title><source>Europace</source><year>2015</year><volume>17</volume><issue>3</issue><fpage>358</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1093/europace/euu265</pub-id><pub-id pub-id-type="pmid">25341740</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>Y</given-names></name></person-group><article-title>Surgical management of mitral annular
calcification</article-title><source>Gen Thorac Cardiovasc Surg</source><year>2013</year><volume>61</volume><issue>11</issue><fpage>619</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1007/s11748-013-0207-7</pub-id><pub-id pub-id-type="pmid">23404309</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>CS</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Parise</surname><given-names>H</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>O'Donnell</surname><given-names>CJ</given-names></name><name><surname>D'Agostino</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Mitral annular calcification predicts cardiovascular morbidity
and mortality: the Framingham heart study</article-title><source>Circulation</source><year>2003</year><volume>107</volume><issue>11</issue><fpage>1492</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.1161/01.cir.0000058168.26163.bc</pub-id><pub-id pub-id-type="pmid">12654605</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Marco</surname><given-names>M</given-names></name><name><surname>Gerdts</surname><given-names>E</given-names></name><name><surname>Casalnuovo</surname><given-names>G</given-names></name><name><surname>Migliore</surname><given-names>T</given-names></name><name><surname>Wachtell</surname><given-names>K</given-names></name><name><surname>Boman</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mitral annular calcification and incident ischemic stroke in
treated hypertensive patients: the LIFE study</article-title><source>Am J Hypertens</source><year>2013</year><volume>26</volume><issue>4</issue><fpage>567</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1093/ajh/hps082</pub-id><pub-id pub-id-type="pmid">23391619</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mottillo</surname><given-names>S</given-names></name><name><surname>Filion</surname><given-names>KB</given-names></name><name><surname>Genest</surname><given-names>J</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><name><surname>Pilote</surname><given-names>L</given-names></name><name><surname>Poirier</surname><given-names>P</given-names></name><etal/></person-group><article-title>The metabolic syndrome and cardiovascular risk a systematic
review and meta-analysis</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>56</volume><issue>14</issue><fpage>1113</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2010.05.034</pub-id><pub-id pub-id-type="pmid">20863953</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Benussi</surname><given-names>S</given-names></name><name><surname>Kotecha</surname><given-names>D</given-names></name><name><surname>Ahlsson</surname><given-names>A</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><name><surname>Casadei</surname><given-names>B</given-names></name><etal/></person-group><article-title>2016 ESC Guidelines for the management of atrial fibrillation
developed in collaboration with EACTS</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><issue>38</issue><fpage>2893</fpage><lpage>2962</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw210</pub-id><pub-id pub-id-type="pmid">27567408</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahn</surname><given-names>DJ</given-names></name><name><surname>DeMaria</surname><given-names>A</given-names></name><name><surname>Kisslo</surname><given-names>J</given-names></name><name><surname>Weyman</surname><given-names>A</given-names></name></person-group><article-title>Recommendations regarding quantitation in M-mode
echocardiography: results of a survey of echocardiographic
measurements</article-title><source>Circulation</source><year>1978</year><volume>58</volume><issue>6</issue><fpage>1072</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1161/01.cir.58.6.1072</pub-id><pub-id pub-id-type="pmid">709763</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohsaka</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Rundek</surname><given-names>T</given-names></name><name><surname>Boden-Albala</surname><given-names>B</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Sacco</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Impact of mitral annular calcification on cardiovascular events
in a multiethnic community: the Northern Manhattan study</article-title><source>JACC Cardiovasc Imaging</source><year>2008</year><volume>1</volume><issue>5</issue><fpage>617</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2008.07.006</pub-id><pub-id pub-id-type="pmid">19356491</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Cleeman</surname><given-names>JI</given-names></name><name><surname>Daniels</surname><given-names>SR</given-names></name><name><surname>Donato</surname><given-names>KA</given-names></name><name><surname>Eckel</surname><given-names>RH</given-names></name><name><surname>Franklin</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Diagnosis and management of the metabolic syndrome: an American
heart association/national heart, lung, and blood institute scientific
statement</article-title><source>Circulation</source><year>2005</year><volume>112</volume><issue>17</issue><fpage>2735</fpage><lpage>2752</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.169404</pub-id><pub-id pub-id-type="pmid">16157765</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tasolar</surname><given-names>H</given-names></name><name><surname>&#x000c7;etin</surname><given-names>M</given-names></name><name><surname>Balli</surname><given-names>M</given-names></name><name><surname>Bayramoglu</surname><given-names>A</given-names></name><name><surname>Otlu</surname><given-names>Y&#x000d6;</given-names></name><name><surname>T&#x000fc;rkmen</surname><given-names>S</given-names></name><etal/></person-group><article-title>CHA2DS2-VASc-HS score in non-ST elevation acute coronary syndrome
patients: assessment of coronary artery disease severity and complexity and
comparison to other scoring systems in the prediction of in-hospital major
adverse cardiovascular events</article-title><source>Anatol J Cardiol</source><year>2016</year><volume>16</volume><issue>10</issue><fpage>742</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.14744/AnatolJCardiol.2015.6593</pub-id><pub-id pub-id-type="pmid">27025198</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capodanno</surname><given-names>D</given-names></name><name><surname>Rossini</surname><given-names>R</given-names></name><name><surname>Musumeci</surname><given-names>G</given-names></name><name><surname>Lettieri</surname><given-names>C</given-names></name><name><surname>Senni</surname><given-names>M</given-names></name><name><surname>Valsecchi</surname><given-names>O</given-names></name><etal/></person-group><article-title>Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in
patients without atrial fibrillation undergoing percutaneous coronary
intervention and discharged on dual antiplatelet therapy</article-title><source>Int J Cardiol</source><year>2015</year><volume>199</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2015.07.064</pub-id><pub-id pub-id-type="pmid">26241637</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boon</surname><given-names>A</given-names></name><name><surname>Cheriex</surname><given-names>E</given-names></name><name><surname>Lodder</surname><given-names>J</given-names></name><name><surname>Kessels</surname><given-names>F</given-names></name></person-group><article-title>Cardiac valve calcification: characteristics of patients with
calcification of the mitral annulus or aortic valve</article-title><source>Heart</source><year>1997</year><volume>78</volume><issue>5</issue><fpage>472</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1136/hrt.78.5.472</pub-id><pub-id pub-id-type="pmid">9415006</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bostr&#x000f6;m</surname><given-names>K</given-names></name><name><surname>Watson</surname><given-names>K</given-names></name><name><surname>Horn</surname><given-names>S</given-names></name><name><surname>Wortham</surname><given-names>C</given-names></name><name><surname>Herman</surname><given-names>I</given-names></name><name><surname>Demer</surname><given-names>L</given-names></name></person-group><article-title>Bone morphogenetic protein expression in human atherosclerotic
lesions</article-title><source>J Clin Invest</source><year>1993</year><volume>91</volume><issue>4</issue><fpage>1800</fpage><lpage>1809</lpage><pub-id pub-id-type="doi">10.1172/JCI116391</pub-id><pub-id pub-id-type="pmid">8473518</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohler 3rd</surname><given-names>ER</given-names></name><name><surname>Gannon</surname><given-names>F</given-names></name><name><surname>Reynolds</surname><given-names>C</given-names></name><name><surname>Zimmerman</surname><given-names>R</given-names></name><name><surname>Keane</surname><given-names>MG</given-names></name><name><surname>Kaplan</surname><given-names>FS</given-names></name></person-group><article-title>Bone formation and inflammation in cardiac valves</article-title><source>Circulation</source><year>2001</year><volume>103</volume><issue>11</issue><fpage>1522</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1161/01.cir.103.11.1522</pub-id><pub-id pub-id-type="pmid">11257079</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kangralkar</surname><given-names>V</given-names></name><name><surname>Patil</surname><given-names>SD</given-names></name><name><surname>Bandivadekar</surname><given-names>R</given-names></name></person-group><article-title>Oxidative stress and diabetes: a review</article-title><source>Int J Pharm Appl</source><year>2010</year><volume>1</volume><issue>1</issue><fpage>38</fpage><lpage>45</lpage></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuentes</surname><given-names>E</given-names></name><name><surname>Palomo</surname><given-names>I</given-names></name></person-group><article-title>Role of oxidative stress on platelet hyperreactivity during
aging</article-title><source>Life Sci</source><year>2016</year><volume>148</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2016.02.026</pub-id><pub-id pub-id-type="pmid">26872977</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francisqueti</surname><given-names>FV</given-names></name><name><surname>Chiaverini</surname><given-names>LCT</given-names></name><name><surname>Santos</surname><given-names>KCd</given-names></name><name><surname>Minatel</surname><given-names>IO</given-names></name><name><surname>Ronchi</surname><given-names>CB</given-names></name><name><surname>Ferron</surname><given-names>AJT</given-names></name><etal/></person-group><article-title>The role of oxidative stress on the pathophysiology of metabolic
syndrome</article-title><source>Rev Assoc Med Bras</source><year>2017</year><volume>63</volume><issue>1</issue><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1590/1806-9282.63.01.85</pub-id><pub-id pub-id-type="pmid">28225880</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briand</surname><given-names>M</given-names></name><name><surname>Lemieux</surname><given-names>I</given-names></name><name><surname>Dumesnil</surname><given-names>JG</given-names></name><name><surname>Mathieu</surname><given-names>P</given-names></name><name><surname>Cartier</surname><given-names>A</given-names></name><name><surname>Despr&#x000e9;s</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Metabolic syndrome negatively influences disease progression and
prognosis in aortic stenosis</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>47</volume><issue>11</issue><fpage>2229</fpage><lpage>2236</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2005.12.073</pub-id><pub-id pub-id-type="pmid">16750688</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briand</surname><given-names>M</given-names></name><name><surname>Pibarot</surname><given-names>P</given-names></name><name><surname>Despr&#x000e9;s</surname><given-names>JP</given-names></name><name><surname>Voisine</surname><given-names>P</given-names></name><name><surname>Dumesnil</surname><given-names>JG</given-names></name><name><surname>Dagenais</surname><given-names>F</given-names></name><etal/></person-group><article-title>Metabolic syndrome is associated with faster degeneration of
bioprosthetic valves</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>1 Suppl</issue><fpage>I512</fpage><lpage>I517</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.000422</pub-id><pub-id pub-id-type="pmid">16820629</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>Budoff</surname><given-names>MJ</given-names></name><name><surname>Takasu</surname><given-names>J</given-names></name><name><surname>Shavelle</surname><given-names>DM</given-names></name><name><surname>Bertoni</surname><given-names>A</given-names></name><name><surname>Blumenthal</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Relationship of metabolic syndrome with incident aortic valve
calcium and aortic valve calcium progression: the multi-ethnic study of
atherosclerosis (MESA)</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><issue>4</issue><fpage>813</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.2337/db08-1515</pub-id><comment>Erratum in: Diabetes. 2009;58(8):1937.</comment><pub-id pub-id-type="pmid">19136658</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name></person-group><article-title>Metabolic syndrome update</article-title><source>Trends Cardiovasc Med</source><year>2016</year><volume>26</volume><issue>4</issue><fpage>364</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2015.10.004</pub-id><pub-id pub-id-type="pmid">26654259</pub-id></element-citation></ref></ref-list></back></article>